Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463918 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers
A Phase 1 study of Smoking Cessation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 16
- Study locations
NCT00463918: Completed Phase 1 study of Smoking Cessation, sponsored by Pfizer.
NCT00463918 is a Phase 1 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 73 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (85% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00463918, a Phase 1 study of Smoking Cessation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.
Conditions Studied
Interventions
- DRUG varenicline
Study Locations (16)
Alabama
- Pfizer Investigational Site - Anniston
- Pfizer Investigational Site - Anniston
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Los Angeles
Florida
- Pfizer Investigational Site - DeLand
- Pfizer Investigational Site - Gainesville
Hawaii
- Pfizer Investigational Site - Honolulu
- Pfizer Investigational Site - Honolulu
Kentucky
- Pfizer Investigational Site - Bardstown
- Pfizer Investigational Site - Lexington
Arizona
- Pfizer Investigational Site - Phoenix
Arkansas
- Pfizer Investigational Site - Hot Springs
Connecticut
- Pfizer Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2007-05 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
What the finished NCT00463918 record still lists
NCT00463918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which varenicline is the first listed.
NCT00463918 lists 16 locations in 11 states (Alabama, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00463918 about?
NCT00463918 is a clinical study titled "A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers". This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.
What is the current status of trial NCT00463918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2007-05. Estimated completion is 2007-12.
What conditions does trial NCT00463918 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00463918?
The interventions under investigation include: varenicline (DRUG).
Who is sponsoring clinical trial NCT00463918?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00463918 being conducted?
This trial has 16 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00463918's enrollment target sits among peer trials
73 130th of 188 higher than 59 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
RECRUITING · Phase 1
-
Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
RECRUITING · Phase 1
-
Harnessing the Power of Technology: MOMBA for Postpartum Smoking
COMPLETED · Phase 1
-
Contingency Management, Quitting Smoking, and ADHD
COMPLETED · Phase 1
-
Intervention for Support Persons to Help Smokers Quit
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia